Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma

  • Chalela, Roberto|||0000-0003-4835-3852
  • González-García, Jose Gregorio
  • Khilzi, Karys
  • Curull Serrano, Víctor|||0000-0003-2709-7431
  • Sánchez Font, Albert|||0000-0003-1026-7908
  • Longarón, Raquel
  • Rodrigo Calvo, María Teresa|||0000-0001-6675-3425
  • Martín-Ontiyuelo, Clara
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically "healthy cells". Objective: to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells in subjects with ADC and negative mutational status. Results: mutations in EGFR or KRAS oncogenes were identified in the normal lung in 9.7% of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS were detected once. One patient presented three different mutations in the normal lung parenchyma (EGFR _L858R, KRAS _G12C and KRAS _G12D). The negative-mutation status of the tumor and the mutations detected in the "normal lung" were confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found in terms of progression, progression-free survival or overall survival during the 18 months follow-up. Conclusions: These results confirm the presence of driver mutations in the histologically normal lung parenchyma cells in the absence of mutations coexisting with the primary tumor.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity

  • Fernandez-Rodríguez, Concepción|||0000-0002-5853-0843
  • Rodriguez-Sevilla, Juan Jose|||0000-0002-4741-7925
  • Fernández Ibarrondo, Lierni|||0000-0003-2612-0484
  • Sánchez González, Blanca
  • Gibert Fernandez, Joan|||0000-0002-0742-0759
  • Bento, Leyre|||0000-0001-9929-8617
  • Garcia, Juan Fernando|||0000-0001-6974-0806
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Díez-Feijoo, Ramón
  • Camacho, Laura
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Gimeno, Eva|||0000-0002-3534-6189
  • Colomo, Luis|||0000-0001-5236-5085
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. AntiHBcore (anti-HBc) cases presented with older age at diagnosis than anti-HBc cases (68.1 vs 57.2 years; P 5.007) and higher b2-microglobulin (56.3% vs 28.9%; P 5.04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P,.0001) and overall survival (OS; 22.0% vs 86.2%; P,.0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.